European Heart Journal-Cardiovascular Pharmacotherapy

Article	Citations
Statin therapy in COVID-19 infection	138
Anticoagulation in COVID-19	82
The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction	64
The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study	55
A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers	51
Effect of statin therapy on SARS-CoV-2 infection-related mortality in hospitalized patients	46
Left ventricular thrombosis: new perspectives on an old problem	45
Continuation versus discontinuation of ACE inhibitors or angiotensin II receptor blockers in COVID-19: effects on blood pressure control and mortality	43
Colchicine as a potent anti-inflammatory treatment in COVID-19: can we teach an old dog new tricks?	43
Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database	41
Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of 605 771 patients	40
Neprilysin inhibitor–angiotensin II receptor blocker combination (sacubitril/valsartan): rationale for adoption in SARS-CoV-2 patients	39
The mechanistic overview of SARS-CoV-2 using angiotensin-converting enzyme 2 to enter the cell for replication: possible treatment options related to the renin–angiotensin system	39
Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis	37
Statin therapy in COVID-19 infection: much more than a single pathway	35
PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY	35
Association between renin–angiotensin system inhibitors and COVID-19 complications	34
Interleukin-1 blockade with anakinra and heart failure following ST-segment elevation myocardial infarction: results from a pooled analysis of the VCUART clinical trials	34
Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk	33
Treatment of Fabry Disease management with migalastat—outcome from a prospective 24 months observational multicenter study (FAMOUS)	33
Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study	33
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlle	31
Renin–angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes from CoViD-19: systematic review and meta-analysis	30
Omega-3 fatty acids supplementation and risk of atrial fibrillation: an updated meta-analysis of randomized controlled trials	29
Apixaban vs. warfarin in patients with left ventricular thrombus: a prospective multicentre randomized clinical trial	27

Patient-reported outcomes and medication adherence in patients with heart failure	26
Impact of opioids on P2Y12 receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: Opioids aNd crushed Ticagrelor In Myocardial infarction	26
Cardiac and cardiometabolic phenotyping of trastuzumab-mediated cardiotoxicity: a secondary analysis of the MANTICORE trial	24
Effect of beta-blocker therapy in patients with or without left ventricular systolic dysfunction after acute myocardial infarction	24
Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis	24
The role of pharmacogenomics in contemporary cardiovascular therapy: a position statement from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy	24
Cardio-renal benefits of sodium–glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence	23
Incidence, associated outcomes, and predictors of upper gastrointestinal bleeding following acute myocardial infarction: a SWEDEHEART-based nationwide cohort study	23
Might renin–angiotensin system blockers play a role in the COVID-19 pandemic?	23
REDUCE-IT INTERIM: accumulation of data across prespecified interim analyses to final results	23
Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation	23
Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment?	22
Antihypertensive drugs in COVID-19 infection	22
What is linking COVID-19 and endothelial dysfunction? Updates on nanomedicine and bioengineering from the 2020 AHA Scientific Sessions	22
Motivational Interviewing to Support Oral AntiCoagulation adherence in patients with non-valvular Atrial Fibrillation (MISOAC-AF): a randomized clinical trial	22
Chloroquine and hydroxychloroquine for COVID-19: implications for cardiac safety	21
Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborat	21
The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer	21
SGLT2 inhibitors in cardiovascular medicine	20
Renal protection in chronic heart failure: focus on sacubitril/valsartan	20
Outcomes of renin–angiotensin–aldosterone system blockers in patients with COVID-19: a systematic review and meta-analysis	19
Different left ventricular remodelling patterns and clinical outcomes between non-ischaemic and ischaemic aetiologies in heart failure patients receiving sacubitril/valsartan treatment	19
SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis	18
Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events	18
The tug-of-war between coagulopathy and anticoagulant agents in patients with COVID-19	18
Management of patients with combined arterial hypertension and aortic valve stenosis: a consensus document from the Council on Hypertension and Council on Valvular Heart Disease of the European Societ	18
2019 ESC/EAS Guidelines for management of dyslipidaemia: strengths and limitations	18
Speculation is not evidence: antihypertensive therapy and COVID-19	17
Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI	17
Effectiveness and safety of oral anticoagulants among non-valvular atrial fibrillation patients with polypharmacy	17
Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy	17
Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT)	17
Duration of dual antiplatelet therapy and subsequent monotherapy type in patients undergoing drug-eluting stent implantation: a network meta-analysis	15
Advances in the understanding of excitation-contraction coupling: the pulsing quest for drugs against heart failure and arrhythmias	15
The interplay between cardiology and diabetology: a renewed collaboration to optimize cardiovascular prevention and heart failure management	15
Safety and efficacy of very low LDL-cholesterol intensive lowering: a meta-analysis and meta-regression of randomized trials	15
Inhibitors of the renin–angiotensin–aldosterone system and COVID-19 in critically ill elderly patients	15
Inclisiran: a new milestone on the PCSK9 road to tackle cardiovascular risk	15
Long-term cardiovascular outcomes after orlistat therapy in patients with obesity: a nationwide, propensity-score matched cohort study	14
Antithrombotic treatment strategies in patients with established coronary atherosclerotic disease	14
Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose–response model	14
Updated meta-analysis of randomized controlled trials on the safety and efficacy of different prophylactic anticoagulation dosing regimens in non-critically ill hospitalized patients with COVID-19	14
Efficacy and Safety of Early Initiation of Eplerenone Treatment in Patients with Acute Heart Failure (EARLIER trial): a multicentre, randomized, double-blind, placebo-controlled trial	13
Patients with diabetes mellitus and atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants: meta-analysis of eight outcomes in 58 634 patients across four randomized controlled	13
Central apnoeas and ticagrelor-related dyspnoea in patients with acute coronary syndrome	13
P2Y12 inhibitors monotherapy after short course of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials including 29 089 p	13
Optimal P2Y12 inhibition in older adults with acute coronary syndromes: a network meta-analysis of randomized controlled trials	13
Assessing absolute stroke risk in patients with atrial fibrillation using a risk factor-based approach	13
Cardiovascular outcomes with GLP-1 receptor agonists vs. SGLT-2 inhibitors in patients with type 2 diabetes	13
The effect of CETP inhibitors on new-onset diabetes: a systematic review and meta-analysis	13

Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side effects: a randomized, double-blinded crossover trial	13
Time to treatment still matters in ST-elevation myocardial infarction: a call to maintain treatment effectiveness during the COVID-19 pandemic	13
Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines	12
Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trials	12
Efficacy and safety of direct oral anticoagulants vs. low molecular weight heparin for cancer-related venous thromboembolism: a meta-analysis of randomized trials	12
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2022	12
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis	12
Direct oral anticoagulants vs. vitamin K antagonists for the treatment of left ventricular thrombosis: a systematic review of the literature and meta-analysis	12
Efficacy and safety of direct oral anticoagulant in morbidly obese patients with atrial fibrillation: systematic review and meta-analysis	12
De-escalation of antiplatelets after percutaneous coronary intervention: a Bayesian network meta-analysis of various de-escalation strategies	11
Long-term prognosis of de novo atrial fibrillation during acute myocardial infarction: the impact of anti-thrombotic treatment strategies	11
Repurposing low-dose naltrexone for the prevention and treatment of immunothrombosis in COVID-19	11
A tale of two therapies lipid-lowering vs. anti-inflammatory therapy: a false dichotomy?	11
Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consens	11
Updated ACC/AHA/HFSA 2022 guidelines on heart failure: what is new? From epidemiology to clinical management	11
Use of sodium-glucose cotransporter-2 inhibitors and the risk for sudden cardiac arrest and for all-cause death in patients with type 2 diabetes mellitus	11
Outcomes after delayed primary percutaneous coronary intervention vs. pharmaco-invasive strategy in ST-segment elevation myocardial infarction in Norway	11
Prescriber responsibility, predictors for initiation, and 20-year trends in use of non-aspirin non-steroidal anti-inflammatory drugs in patients with cardiovascular contraindications: a nationwide coh	10
Potential effects of icosapent ethyl on cardiovascular outcomes in cigarette smokers: REDUCE-IT smoking	10
Systemic fibrinolysis for acute pulmonary embolism complicating acute respiratory distress syndrome in severe COVID-19: a case series	10
Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing	10
Has the ‘strength’ of fish oil therapy been ‘reduced’? Reconciling the results of REDUCE-IT and STRENGTH	10
Extended, standard, or De-escalation antiplatelet therapy for patients with coronary artery disease undergoing percutaneous coronary intervention? A trial-sequential, bivariate, influential, and netwo	10
Effect of ticagrelor monotherapy on mortality after percutaneous coronary intervention: a systematic review and meta-analysis of randomized trials including 26 143 patients	10
Incidence of cerebral venous thrombosis and COVID-19 vaccination: possible causal effect or just chance?	10
Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial	10
Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry	10
Risk of infections in patients treated with ticagrelor vs. clopidogrel: a systematic review and meta-analysis	10
Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on	10
Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk: the FORWARD study	10
Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: a nationwide registry analysis	9
Choices in antithrombotic management for patients with atrial fibrillation undergoing percutaneous coronary intervention: questions (and answers) in chronological sequence	9
Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial	9
Sacubitril/valsartan in COVID-19 patients: the need for trials	9
Adherence to prescribed medications in patients with heart failure: insights from liquid chromatography–tandem mass spectrometry-based urine analysis	9
Digoxin use in contemporary heart failure with reduced ejection fraction: an analysis from the Swedish Heart Failure Registry	9
Antiplatelet therapy in patients with atrial fibrillation: a systematic review and meta-analysis of randomized trials	9
Cancer treatment and atrial fibrillation: use of pharmacovigilance databases to detect cardiotoxicity	9
Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care	9
Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial	9
Impact of white blood cell count on clinical outcomes in patients treated with aspirin-free ticagrelor monotherapy after percutaneous coronary intervention: insights from the GLOBAL LEADERS trial	9
Antithrombotic drug removal from whole blood using Haemoadsorption with a porous polymer bead sorbent	8
Off-label use of reduced dose direct oral factor Xa inhibitors in subjects with atrial fibrillation: a review of clinical evidence	8
LDL lowering effect of PCSK9 inhibition is reduced in women	8
Colchicine and risk of non-cardiovascular death in patients with coronary artery disease: a pooled analysis underling possible safety concerns	8
Recombinant human lecithin-cholesterol acyltransferase in patients with atherosclerosis: phase 2a primary results and phase 2b design	8
Ticagrelor and the risk of Staphylococcus aureus bacteraemia and other infections	8
Efficacy of sodium-glucose cotransporter-2 inhibitors in heart failure patients treated with dual angiotensin receptor blocker-neprilysin inhibitor: an updated meta-analysis	8
Cardiac safety and potential efficacy: two reasons for considering minocycline in place of azithromycin in COVID-19 management	8
Cardiovascular pharmacotherapy in older people: challenges posed by cardiovascular drug prescription in the elderly	7
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy	7
Unravelling the puzzle of antithrombotic therapies for complex percutaneous coronary intervention	7
Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled tr	7
Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction, and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis	7
An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis: results from 19 countries	7
ESC/EAS guidelines for the detection, prevention, and treatment of individuals at risk of a first myocardial infarction: effect of 5 years of updates and the new SCORE2	7
Anticoagulation in atrial fibrillation and liver disease: a pooled-analysis of >20 000 patients	6
Cardiovascular risks associated with calcium supplementation in patients with osteoporosis: a nationwide cohort study	6
Minimizing bleeding events	6
Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis	6
Associations between medical therapy after surgical aortic valve replacement for aortic stenosis and long-term mortality: a report from the SWEDEHEART registry	6
Photoinduced skin reactions of cardiovascular drugs—a systematic review	6
Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD	6
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease	6
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial	6
Head-to-head efficacy and safety of rivaroxaban, apixaban, and dabigatran in an observational nationwide targeted trial	6
Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial	6
The association of PRECISE-DAPT score with ischaemic outcomes in patients taking dual antiplatelet therapy following percutaneous coronary intervention: a meta-analysis	5
External validity of the PRECISE-DAPT score in patients undergoing PCI: a systematic review and meta-analysis	5
β-blocker and 1-year outcomes among patients hospitalized for heart failure with mid-range ejection fraction	5
FLOW trial stopped early due to evidence of renal protection with semaglutide	5
Differential effects of dual antiplatelet therapy in patients presented with acute coronary syndrome vs. stable ischaemic heart disease after coronary artery bypass grafting	5
Effects of renin–angiotensin system inhibitor type and dosage on survival after transcatheter aortic valve implantation	5
The importance of adherence and persistence with oral anticoagulation treatment in patients with atrial fibrillation	5
Subgroup analyses in randomized clinical trials: value and limitations. Review #3 on important aspects of randomized clinical trials in cardiovascular pharmacotherapy	5
The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid, diabetes, and antithrombotic trials	5
Design and rationale of randomized evaluation of decreased usage of beta-blockers after acute myocardial infarction (REDUCE-AMI)	5
The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials	5
Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry	5
Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48	5

Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study	5
RNA-targeted therapeutics in cardiovascular disease: the time is now	5
Comparison between ticagrelor and clopidogrel in myocardial infarction patients with high bleeding risk	5
Intensive blood pressure control in patients with a history of heart failure: the Systolic Blood Pressure Intervention Trial (SPRINT)	4
Combinations of antithrombotic therapies prescribed after percutaneous coronary intervention in patients with acute coronary syndromes and atrial fibrillation: data from the nationwide MATADOR-PCI reg	4
Neuraminidase inhibitor treatment is associated with decreased mortality in COVID-19 patients: a retrospective analysis	4
Aspirin adherence in subjects with glucose-6-phosphate-dehydrogenase deficiency having an acute coronary syndrome	4
Adenosine as adjunctive therapy in acute coronary syndrome: a meta-analysis of randomized controlled trials	4
Association of guideline-directed medical therapy adherence with outcomes after fractional flow reserve-based deferral of revascularization	4
Antiplatelet effect, safety, and pharmacokinetics of vicagrel in patients with coronary artery disease undergoing percutaneous coronary intervention	4
A novel, small-volume subcutaneous furosemide formulation delivered by an abdominal patch infusor device in patients with heart failure: results of two phase I studies	4
Antithrombotic therapy following revascularization for chronic limb-threatening ischaemia: a European survey from the ESC Working Group on Aorta and Peripheral Vascular Diseases	4
Risk of fracture in patients with non-valvular atrial fibrillation initiating direct oral anticoagulants vs. vitamin K antagonists	4
Impact of ethnicity on antiplatelet treatment regimens for bleeding reduction in acute coronary syndromes: a systematic review and pre-specified subgroup meta-analysis	4
Platelet activation and endothelial dysfunction biomarkers in acute coronary syndrome: the impact of PCSK9 inhibition	4
Concerns about the use of digoxin in acute coronary syndromes	4
Cardiovascular, renal, and lower limb outcomes in patients with type 2 diabetes after percutaneous coronary intervention and treated with sodium–glucose cotransporter 2 inhibitors vs. dipeptidyl pepti	4
A dose–response relationship of renin–angiotensin system blockers and beta-blockers in patients with acute heart failure syndrome: a nationwide prospective cohort study	4
Protective association of angiotensin blockade with influenza: a result of immortal time bias?	4
Statin therapy and SAR-COV-2: an available and potential therapy?	4
The burden of cholesterol accumulation through the lifespan: why pharmacological intervention should start earlier to go further?	4
Are SGLT2 inhibitors effective against ‘all’ heart failure with preserved ejection fraction?	4
Depressive symptoms and non-adherence to treatable cardiovascular risk factors’ medications in the CONSTANCES cohort	4
The effect of SGLT2 inhibitors on the endothelium and the microcirculation: from bench to bedside and beyond	4
Discontinuation of direct oral anticoagulants among patients with atrial fibrillation according to gender and cohabitation status: a nationwide cohort study	4
Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy	4
Early glycaemic changes after initiation of oral antidiabetic medication and risk of major adverse cardiovascular events: results from a large primary care population of patients with type 2 diabetes	3
Vericiguat in the management of heart failure with reduced ejection fraction	3
Pragmatic approaches to the next generation of clinical trials in heart failure	3
Medication in adults after atrial switch for transposition of the great arteries: clinical practice and recommendations	3
Cost-effectiveness of clopidogrel vs. ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndrome	3
Intensive blood pressure control appears to be effective and safe in patients with peripheral artery disease: the Systolic Blood Pressure Intervention Trial	3
Epinephrine administration for adult out-of-hospital cardiac arrest patients with refractory shockable rhythm: time-dependent propensity score-sequential matching analysis from a nationwide population	3
Cost–effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial	3
Weekend vs. weekday admission and clinical outcomes in heart failure patients with and without atrial fibrillation in Taiwan	3
Vascular mechanisms of post-COVID-19 conditions: Rho-kinase is a novel target for therapy	3
Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve implantation in patients without indications for chronic oral anticoagulation: a systematic review and network meta-	3
Heart failure pharmacological treatments and outcomes in heart failure with mildly reduced ejection fraction	3
Focus on subpopulations of atrial fibrillation patients	3
Aspirin, NOACs, warfarin: which is the best choice to tackle cognitive decline in elderly patients? Insights from the GIRAF and ASCEND-Dementia trials presented at the AHA 2021	3
Sex-based differences in risk of ischaemic stroke or systemic embolism after BNT162b2 or CoronaVac COVID-19 vaccination in patients with atrial fibrillation: a self-controlled case series and nested c	3
Haematuria and urinary tract cancers in patients with atrial fibrillation treated with oral anticoagulants	3
The SAMSON trial: using a placebo to improve medication tolerability	3
The neurocognitive effects of atrial fibrillation: benefits of the ABC pathway	3
The potential of colchicine for lowering the risk of cardiovascular events in type 1 diabetes	3
2022 ESC Guidelines on cardio-oncology: how can we improve the cardiovascular health of patients with cancer and cancer survivors?	3
Use of methylphenidate is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nationwide nested case-control study	3
Clinical outcomes in elderly atrial fibrillation patients at increased bleeding risk treated with very low dose vs. regular-dose non-vitamin K antagonist oral anticoagulants: a nationwide cohort study	3
Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition	3
A systematic review and meta-analyses on the effects of atorvastatin on blood pressure and heart rate	3
Oral antithrombotic therapy for the prevention of recurrent cerebrovascular events	3
New cardiology aspects of triple antithrombotic therapy, diabetes without insulin therapy as a risk factor in atrial fibrillation, treatment of gout, cholesterol lowering treatment, prostate cancer tr	3
Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial	3
Beta blockers and long-term outcome after coronary artery bypass grafting: a nationwide observational study	3
Beta-blocker therapy after myocardial infarction guided by left ventricular ejection fraction: is 50 the new 40?	3